Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLA2G2A | P14555 | 2/20 | 0.60 |
| ▸ | LMNA | P02545 | 2/20 | 0.55 |
| ▸ | PPARG | P37231 | 2/20 | 0.55 |
| ▸ | PPARD | Q03181 | 2/20 | 0.55 |
| ▸ | PPARA | Q07869 | 2/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.55 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.52 |
| ▸ | CHRNB2 | P17787 | 3/20 | 0.51 |
| ▸ | CHRNA7 | P36544 | 3/20 | 0.51 |
| ▸ | CHRNA4 | P43681 | 3/20 | 0.51 |
| ▸ | ICMT | O60725 | 2/20 | 0.50 |
| ▸ | HTR6 | P50406 | 1/20 | 0.50 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.49 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.49 |
| ▸ | TP53 | P04637 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8174618 | 0.93 | LMNA (0.56) | PLA2G2ALMNAPPARGPPARDPPARA | |
| SCHEMBL8178907 | 0.92 | ALDH1A1 (0.56) | PLA2G2ALMNAPPARGPPARDPPARA | |
| SCHEMBL13931408 | 0.91 | ALDH1A1 (0.58) | PLA2G2ALMNAPPARGPPARDPPARA | |
| SCHEMBL8182990 | 0.88 | PPARG (0.62) | PLA2G2ALMNAPPARGPPARDPPARA | |
| SCHEMBL8175011 | 0.88 | PPARD (0.65) | PLA2G2ALMNAPPARGPPARDPPARA | |
| SCHEMBL8173991 | 0.87 | ALDH1A1 (0.58) | PLA2G2ALMNAPPARGPPARDPPARA | |
| SCHEMBL7692305 | 0.87 | CHRM1 (0.65) | PLA2G2ALMNAPPARGPPARDPPARA | |
| SCHEMBL8180736 | 0.86 | ALDH1A1 (0.55) | PLA2G2ALMNAPPARGPPARDPPARA | |
| SCHEMBL13931407 | 0.85 | ALDH1A1 (0.60) | PLA2G2ALMNAPPARGPPARDPPARA | |
| SCHEMBL8180790 | 0.84 | PLA2G2A (0.53) | PLA2G2ALMNAPPARGPPARDPPARA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090047246-A1 | NOVEL INHIBITORS OF HEPATITIS C VIRUS REPLICATION | INTERMUNE, INC. (US) | 2009-02-19 | — | — | US | disclosed |
| US-20090047246-A1 | NOVEL INHIBITORS OF HEPATITIS C VIRUS REPLICATION | INTERMUNE, INC. (US) | 2009-02-19 | — | — | US | disclosed |
| WO-2008100867-A2 | NOVEL INHIBITORS HEPATITIS C VIRUS REPLICATION | INTERMUNE, INC. (US) | 2008-08-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090047246-A1 | NOVEL INHIBITORS OF HEPATITIS C VIRUS REPLICATION | EIF2AK2, HAVCR2, HCCS | PLA2G2A 3963/4885LMNA 2969/4885PPARG 3213/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.